ViaLongeVita

This article was automatically translated into your selected language.(mymemory)

새로운 GPRC5D × CD3 bispecific talquetamab-treated 재발/refractory multiple myeloma 환자에서 GPRC5D-associated 부작용의 임상 특징 및 관리 : MonumenTAL-1 중국 cohort 경험VIP

혈액학 — An G, Jin J, Cai Z

이 콘텐츠는 의학적 진단이나 치료 권고가 아닙니다. 항상 의사와 상담하세요.

Illustration for "새로운 GPRC5D × CD3 bispecific talquetamab-treated 재발/refractory multiple myeloma 환자에서 GPRC5D-associated 부작용의 임상 특징 및 관리 : MonumenTAL-1 중국 cohort 경험" — longevity and healthy aging, diverse group of adults

Enjoying this article? Support the editorial team with a tip

혈액학 — An G, Jin J, Cai Z

Exkluzivně pro předplatitele

Pokračujte ve čtení s MedScope Premium

VIP články obsahují klinické dopady, klíčové body a ověřené zdroje — navržené pro studenty a lékaře.

14 dní zkušební verze zdarma — vyzkoušejte bez rizika

Vybrat plán

Již máte účet? Přihlásit se · Srovnání tarifů

Support the author (MedScopeGlobal Editorial) · Tip

Optional micro-contribution — like a tip. Funds ViaLongeVita editorial.

A tip is not a VIP subscription and does not unlock paid content — it is optional support for the desk.

Contribution

Donate

A micro-donation helps us keep publishing quality content.

Related reading

Recommended content

Prepared by the MedScopeGlobal.com editorial team — educational health content for the public. Always consult a physician for personal medical decisions.